Abstract

Tenapanor for the Treatment of Irritable Bowel Syndrome With Constipation

Clin Pharmacol. 2020 Jun 1;1-7. doi: 10.1080/17512433.2020.1762570.Online ahead of print.

Emanuele Sinagra 1 2, Francesca Rossi 1, Dario Raimondo 1, Giuseppe Conoscenti 1, Andrea Anderloni 3, Valentina Guarnotta 4, Marcello Maida 5

 
     

Author information

1Gastroenterology and Endoscopy Unit, Fondazione Istituto G. Giglio, Contrada Pietra Pollastra Pisciotto , Cefalù, Italy.

2Section of Nutrition, Euro-Mediterranean Institute of Science and Technology (IEMEST) , Palermo, Italy.

3Digestive Endoscopy Unit, Division of Gastroenterology, Humanitas Research Hospital , Rozzano Italy.

4Dipartimento Di Promozione Della Salute, Materno-Infantile, Medicina Interna E Specialistica Di Eccellenza "G. D'Alessandro" (PROMISE), Sezione Di Malattie Endocrine, Del Ricambio E Della Nutrizione, Università Di Palermo , Italy.

5Section of Gastroenterology, S.Elia - Raimondi Hospital , Caltanissetta, Italy.

Abstract

Introduction: Irritable bowel syndrome with constipation is associated with higher rates of functional impairment, as compared to other subtypes of the syndrome. Conventional laxative-based pharmacologic therapy of IBS-C, which is mostly symptom-based, is often unsatisfactory. Tenapanor represents a first-in-class orally available inhibitor of NHE3, which is minimally absorbed in the GI tract, what constitutes a significant therapeutic benefit, as it may act on the drug target.

Areas covered: Aim of this article is to sum up the evidences about pharmacodynamics and pharmacokinetics of tenapanor, focusing on animal models and in vitro studies, but also discuss clinical trials on tenapanor's safety and efficacy in view of its important potential role in IBS-C treatment.

Expert opinion: In the challenging setting of irritable bowel syndrome with constipation, tenapanor represents a novel strategy in the pipeline of the therapies of IBS-C. Its pharmacokinetic and pharmacodynamic profile provides that it is minimally absorbed from the intestinal lumen and that its action is local, but not systemic action, therefore guaranteeing the reduction of drug-drug interactions, toxicity and severe adverse effects. Phase 2b and 3 trials showed an optimal satisfaction of primary and secondary endpoints.

© Copyright 2013-2020 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.